The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors
Published version of a preprint
Abstract
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Levinson and co-workers found that binding of type II inhibitors to BRAF cause an asymmetric allosteric coupling that is essential for activating the BRAF homodimer, whereas type I inhibitors lack this capacity [40].”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [40]
In the citing paper
“The concept of binding cooperativity has shed light on the paradoxical activation of the BRAF kinase cascade by small drug-like molecules initially designed as BRAF inhibitors [40].”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.001 · Cited by 543
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00725-y · Cited by 65
Self-citationKholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
Research works printed but not linked: 51
- Brian, 2020, Immunopharmacology and quantitative analysis of tyrosine kinase signaling, Current Protocols in Immunology, 130, 10.1002/cpim.104 · DOI
- Brian, 2022, A dominant function of LynB kinase in preventing autoimmunity, Science Advances, 8, 10.1126/sciadv.abj5227 · DOI
- Brummer, 2020, RAF kinase dimerization: implications for drug discovery and clinical outcomes, Oncogene, 39, 4155, 10.1038/s41388-020-1263-y · DOI
- Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, The New England Journal of Medicine, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
- Cook, 2021, Inhibition of RAF dimers: it takes two to tango, Biochemical Society Transactions, 49, 237, 10.1042/BST20200485 · DOI
- Cotto-Rios, 2020, Inhibitors of BRAF dimers using an allosteric site, Nature Communications, 11, 10.1038/s41467-020-18123-2 · DOI
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial, The Lancet. Oncology, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI · Paper page
- Ederer, 2007, Thermodynamically feasible kinetic models of reaction networks, Biophysical Journal, 92, 1846, 10.1529/biophysj.106.094094 · DOI
- Eisen, 2006, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, British Journal of Cancer, 95, 581, 10.1038/sj.bjc.6603291 · DOI · Paper page
- Hagelueken, 2012, MtsslWizard: in silico spin-labeling and generation of distance distributions in PyMOL, Applied Magnetic Resonance, 42, 377, 10.1007/s00723-012-0314-0 · DOI
- Haling, 2014, Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling, Cancer Cell, 26, 402, 10.1016/j.ccr.2014.07.007 · DOI · Paper page
- Hall-Jackson, 1999, Paradoxical activation of Raf by a novel Raf inhibitor, Chemistry & Biology, 6, 559, 10.1016/s1074-5521(99)80088-x · DOI · Paper page
- Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
- Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
- Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
- Hu, 2013, Allosteric activation of functionally asymmetric RAF kinase dimers, Cell, 154, 1036, 10.1016/j.cell.2013.07.046 · DOI · Paper page
- Jin, 2017, RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition, Nature Communications, 8, 10.1038/s41467-017-01274-0 · DOI
- Johnson, 2009, FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data, Analytical Biochemistry, 387, 30, 10.1016/j.ab.2008.12.025 · DOI · Paper page
- Joseph, 2010, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner, PNAS, 107, 14903, 10.1073/pnas.1008990107 · DOI · Paper page
- Karoulia, 2016, An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling, Cancer Cell, 30, 485, 10.1016/j.ccell.2016.06.024 · DOI · Paper page
- Kondo, 2019, Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases, Science, 366, 109, 10.1126/science.aay0543 · DOI · Paper page
- Lai, 2022, Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors, PNAS, 119, 10.1073/pnas.2113491119 · DOI
- Lavoie, 2013, Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization, Nature Chemical Biology, 9, 428, 10.1038/nchembio.1257 · DOI · Paper page
- Lavoie, 2015, Regulation of RAF protein kinases in ERK signalling, Nature Reviews. Molecular Cell Biology, 16, 281, 10.1038/nrm3979 · DOI · Paper page
- Lavoie, 2018, MEK drives BRAF activation through allosteric control of KSR proteins, Nature, 554, 549, 10.1038/nature25478 · DOI
- Liau, 2020, Dimerization induced by C-Terminal 14-3-3 binding is sufficient for BRAF kinase activation, Biochemistry, 59, 3982, 10.1021/acs.biochem.0c00517 · DOI
- Martinez Fiesco, 2022, Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding, Nature Communications, 13, 10.1038/s41467-022-28084-3 · DOI
- Nakamura, 2013, Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma, Cancer Research, 73, 7043, 10.1158/0008-5472.CAN-13-1825 · DOI
- Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 · DOI · Paper page
- Okaniwa, 2013, Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives, Journal of Medicinal Chemistry, 56, 6478, 10.1021/jm400778d · DOI
- Owsley, 2021, Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database, Experimental Biology and Medicine, 246, 31, 10.1177/1535370220959657 · DOI
- Park, 2019, Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes, Nature, 575, 545, 10.1038/s41586-019-1660-y · DOI · Paper page
- Peng, 2015, Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers, Cancer Cell, 28, 384, 10.1016/j.ccell.2015.08.002 · DOI · Paper page
- Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
- Proietti, 2020, Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review, Cancers, 12, 10.3390/cancers12102801 · DOI
- Rajakulendran, 2009, A dimerization-dependent mechanism drives RAF catalytic activation, Nature, 461, 542, 10.1038/nature08314 · DOI · Paper page
- Röring, 2012, Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling, The EMBO Journal, 31, 2629, 10.1038/emboj.2012.100 · DOI
- Rushworth, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Molecular and Cellular Biology, 26, 2262, 10.1128/MCB.26.6.2262-2272.2006 · DOI · Paper page
- Schaaf, 2017, Spectral unmixing plate reader: high-throughput, high-precision FRET assays in living cells, SLAS Discovery, 22, 250, 10.1177/1087057116679637 · DOI
- Su, 2012, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors, The New England Journal of Medicine, 366, 207, 10.1056/NEJMoa1105358 · DOI · Paper page
- Sullivan, 2020, A phase i study of LY3009120, A Pan-RAF inhibitor, in patients with advanced or metastatic cancer, Molecular Cancer Therapeutics, 19, 460, 10.1158/1535-7163.MCT-19-0681 · DOI
- Thevakumaran, 2015, Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation, Nature Structural & Molecular Biology, 22, 37, 10.1038/nsmb.2924 · DOI · Paper page
- Thompson A. 2022. Venison. Software Heritage. swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8. https://archive.softwareheritage.org/swh:1:dir:1d1c3270a76015e6f0a2b96ef99a7c134027e4e7;origin=https://github.com/thompsar/Venison;visit=swh:1:snp:71e7db0713a1908384d6d87dbe47c158ef2e85eb;anchor=swh:1:rev:652831dae45127fe2ff7cdf0188d9703d9e768f8.
- Tkacik, 2023, Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib, The Journal of Biological Chemistry, 299, 10.1016/j.jbc.2023.104634 · DOI
- Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, PNAS, 105, 3041, 10.1073/pnas.0711741105 · DOI · Paper page
- Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, Journal of Clinical Oncology, 29, 3085, 10.1200/JCO.2010.33.2312 · DOI · Paper page
- Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/s0092-8674(04)00215-6 · DOI · Paper page
- Weber, 2001, Active ras induces heterodimerization of cRaf and BRaf, Cancer Research, 61, 3595
- Wellbrock, 2004, The RAF proteins take centre stage, Nature Reviews. Molecular Cell Biology, 5, 875, 10.1038/nrm1498 · DOI · Paper page
- Ye, 2017, Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans, Cancer Chemotherapy and Pharmacology, 79, 507, 10.1007/s00280-017-3240-x · DOI
Cited by
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Olivieri, C., Wu, J., Taylor, S. S., & Veglia, G. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103169 · Cited by 1
Local and distal changes in dynamics are caused by an L205R Cushing’s syndrome mutant in PRKACA
Kalle, A., Wu, J., Tawfeeq, C., Kornev, A. P., Veglia, G., Maillard, R., Taylor, S. S., & Jonniya, N. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502898122 · Cited by 1
Metadata
- Authors
- Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Toledo Ramos, S., Thomas, D. D., Pomerantz, W. C., Freedman, T. S., & Levinson, N. M.
- Affiliations
- Department of Pharmacology, University of Minnesota
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota
- Department of Chemistry, University of Minnesota
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2024-05-14
- Volume
- 13
- ISSN
- 2050-084X
- Cited by
- 14
- References
- 6
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- National Cancer Institute (F31CA257218, R33CA246363)
- National Institute of General Medical Sciences (T32GM132029, 5R35GM140837)
- American Cancer Society – Kirby Foundation (PF-21-068-01-LIB)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR073966)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors. https://app.cochat.ai/papers/10.7554/elife.95481.2
- The paper
- Rasmussen, D. M., Semonis, M. M., Greene, J. T., Muretta, J. M., Thompson, A. R., Toledo Ramos, S., Thomas, D. D., Pomerantz, W. C., Freedman, T. S., & Levinson, N. M. (2024). Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors. eLife. https://doi.org/10.7554/elife.95481.2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.